November 1, 2023

PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partner Geneyx to PacBio Compatible

PacBio

Partnerships Maximize Value of HiFi Data and Complete the Full End-to-End Workflow for PacBio Customers.

MENLO PARK, Calif.Nov. 1, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the addition of two tertiary analysis partners to PacBio Compatible. Geneyx will enable PacBio customers to leverage PacBio HiFi data for disease research with the Revio, Sequel II and IIe sequencing systems.

Interpreting sequencing data generally involves primary, secondary, and tertiary analysis. Tertiary analysis powers knowledge discovery from variants, usually including annotation, filtering, and data visualization, and can provide further support for phasing and analyzing complex events such as structural variation. These new partnerships are designed to maximize the value of HiFi data and complete the full end-to-end workflow for PacBio customers.

“Primary and secondary analysis solutions are available through our SMRT Analysis Software, the recently released PacBio WGS Variant Pipeline, and analysis partners such as GoogleHealth, all of which provide the best quality of data to power biological interpretation,” said Jeff Eidel, Chief Commercial Officer at PacBio. “Through our new partnerships with Geneyx, researchers can accelerate their discoveries and find solutions from sample to answer across their HiFi-based workflows.” 

Publications show that HiFi sequencing finds more structural variants (SVs) than short reads.1 SVs are important as they account for much of the genetic diversity between humans and have been shown to be associated with disease pathogenesis. Our tertiary analysis partners can further accelerate customers’ interpretation of this important variant class and enable PacBio customers to create a biological interpretation more easily from the underlying genomic content of their samples, maximizing the impact of PacBio sequencing on human health.

“Geneyx takes great pride in its partnership with PacBio. This collaboration leverages our HiFi sequencing data analysis expertise, enabling us to provide a comprehensive solution for long-read whole genome sequencing analysis. Our specialized tools, including phasing and methylation analysis, are tailored to PacBio data, simplify the bioinformatics process, and ensure accurate variant annotation and classification,” said David Yizhar, Chief Executive Officer of Geneyx. “Geneyx serves a diverse global user base, including PacBio customers. Together, our efforts will advance the realms of research.”

PacBio Compatible works with a wide range of organizations to ensure customers can find verified products that are complementary to their workflows for PacBio sequencing. Partners collaborate closely with PacBio scientists to provide seamless integration and support for customers who are just starting out with PacBio or expanding their current capabilities.

About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, third-party compatibility, cost advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies; the ability to leverage PacBio HiFi data for disease research and provide complete solutions and end-to-end workflows; the acceleration of discoveries, interpretations and solutions; the impact of PacBio sequencing on human health; and other forward-looking statements. Reported results and orders for any instrument system should not be considered an indication of future performance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in developing, manufacturing, launching, marketing and selling new products; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; potential product performance and quality issues and potential delays in development timelines; the possible loss of key suppliers; and, third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio’s patents or proprietary rights. Additional factors that could materially affect actual results can be found in PacBio’s most recent filings with the Securities and Exchange Commission, including PacBio’s most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

Contacts

Investors:
Todd Friedman
ir@pacificbiosciences.com 

Media:
Lizelda Lopez
pr@pacificbiosciences.com

 

1 Ebert, P. et al. (2021) Haplotype-resolved diverse human genomes and integrated analysis of structural variation. Science. (available here: https://pubmed.ncbi.nlm.nih.gov/33632895/)

 

SOURCE Pacific Biosciences of California, Inc.

View all our latest news here

Additional Articles

News

Geneyx Among the World's Best Digital Health Companies in 2024

May 15, 2024

Geneyx Among the World’s Best Digital Health Companies in 2024

Newsweek

This acknowledgment highlights Geneyx's significant contributions to the rapidly expanding digital health sector.

Children's Mercy Kansas City and Geneyx Inc. Announce Collaboration to Advance Genomic Research and Analysis

March 13, 2024

Children’s Mercy Kansas City and Geneyx Inc. Announce Collaboration to Advance Genomic Research and Analysis

PR Newswire

Children's Mercy Kansas City, one of the leading independent pediatric health organizations, and Geneyx Inc. are pleased to announce a collaboration aimed at advancing genomic research and analysis.

PacBio Geneyx Press Release

November 1, 2023

PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partner Geneyx to PacBio Compatible

PacBio

Partnerships maximize value of HiFi data and complete the full end-to-end workflow for PacBio customers.

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

July 26, 2023

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

Geneyx

Geneyx and Ocean Genomics develop a multiomic software method, combining DNA and RNA.

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

July 26, 2023

BIRD Foundation invests $8 million in 9 new projects

James Spiro

Geneyx and Ocean Genomics will develop a multiomic software method, combining DNA and RNA.

Bioinformatics Startup Geneyx Builds Business on Whole-Genome, Long-Read Sequencing Analysis

June 21, 2023

Bioinformatics Startup Geneyx Builds Business on Whole-Genome, Long-Read Sequencing Analysis

Neil Versel

This month's announcement that Oxford Nanopore Technologies would integrate its Epi2Me cloud-based analysis platform with Geneyx's software to automate analysis and clinical reporting of long-read sequencing data

Previous
Next
Geneyx Among the World's Best Digital Health Companies in 2024

May 15, 2024

Geneyx Among the World’s Best Digital Health Companies in 2024

Newsweek

This acknowledgment highlights Geneyx's significant contributions to the rapidly expanding digital health sector.

Children's Mercy Kansas City and Geneyx Inc. Announce Collaboration to Advance Genomic Research and Analysis

March 13, 2024

Children’s Mercy Kansas City and Geneyx Inc. Announce Collaboration to Advance Genomic Research and Analysis

PR Newswire

Children's Mercy Kansas City, one of the leading independent pediatric health organizations, and Geneyx Inc. are pleased to announce a collaboration aimed at advancing genomic research and analysis.

PacBio Geneyx Press Release

November 1, 2023

PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partner Geneyx to PacBio Compatible

PacBio

Partnerships maximize value of HiFi data and complete the full end-to-end workflow for PacBio customers.

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

July 26, 2023

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

Geneyx

Geneyx and Ocean Genomics develop a multiomic software method, combining DNA and RNA.

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

July 26, 2023

BIRD Foundation invests $8 million in 9 new projects

James Spiro

Geneyx and Ocean Genomics will develop a multiomic software method, combining DNA and RNA.

Bioinformatics Startup Geneyx Builds Business on Whole-Genome, Long-Read Sequencing Analysis

June 21, 2023

Bioinformatics Startup Geneyx Builds Business on Whole-Genome, Long-Read Sequencing Analysis

Neil Versel

This month's announcement that Oxford Nanopore Technologies would integrate its Epi2Me cloud-based analysis platform with Geneyx's software to automate analysis and clinical reporting of long-read sequencing data

+

Selected Videos

Geneyx Analysis Version 5.12 Release

Previous
Next

Schedule Demo

Contact us to set a live demo


Contact Us

Whether you have general questions about our solutions or would like to schedule a demo or to suggest collaboration – our team is on hand for you.